EX-10.1
from 10-Q
20 pages
Whereas, Anthra Pharmaceuticals, Inc. (“Anthra”) and Genchem Pharma Ltd. Are Parties to That Certain Supply Agreement Dated as of September 11, 1997 Pursuant to Which, Among Other Things, Anthra Agreed to Purchase N-Trifluoroacetyl-Adriamycin-14 Valarate, Upon the Terms and Conditions Set Forth in Such Agreement; Whereas, Pursuant to That Certain Asset Purchase Agreement Dated September 29, 2005, Valera Has Acquired Substantially All of the Assets of Anthra Associated With Its Valrubicin Business in the United States and Canada Including Rights of Anthra Under the Anthra Agreement (As Defined Below); Whereas, Plantex and Valera Desire to Provide for the Manufacture, Supply and Purchase of the Active Pharmaceutical Product Valrubicin, Upon the Terms and Conditions Set Forth in This Agreement; Now, Therefore, in Consideration of the Premises and of the Mutual Covenants and Agreements Set Forth in This Agreement, and Other Good and Valuable Consideration the Adequacy and Sufficiency of Which Is Acknowledged, the Parties, Intending to Be Legally Bound, Agree as Follows: 1. Interpretation and Certain Definitions
12/34/56
